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A report on the 14th Lorne Cancer Conference, Lorne,
Victoria, Australia, 14-17 February 2002.
The ‘guardian of the genome’, the p53 protein, a key regulator
of cell cycle arrest and apoptosis, featured prominently at
this year’s Lorne Cancer Conference. The plenary seminar
was presented by David Lane (University of Dundee, UK),
whose  research  has  been  central  to  the  transformation  of
p53  from  being  considered  a  weak  oncogene  to  its  now
clearly demonstrated role as a powerful tumor suppressor.
There  were  also  several  reports  on  pathways  mediated  by
another tumor suppressor, the retinoblastoma protein (pRb)
as well as updates on an ever-increasing array of proteins
and signaling pathways implicated in cancer. We learned of
several animal models for cancer and how they may be used
to screen for as-yet unidentified oncogenes or tumor sup-
pressors;  and  we  heard  about  attempts  to  develop  cancer
vaccines, p53-targeted tumor therapy, and the use of metallo-
proteinase inhibitors in cancer treatment. The following are
some of the highlights.
Upstream and downstream of p53 and pRb
The activation of p53 in response to DNA-damaging agents
and other forms of stress is part of a protective mechanism
that  ensures  cell-cycle  arrest  and  DNA  repair  or,  alterna-
tively, apoptosis. Many tumor cells lack p53 function, and it
seems  there  is  enormous  potential  for  therapy  based  on
restoring p53 function, either directly or by inhibiting the E3
ubiquitin  ligase  MDM2  that  regulates  p53  degradation.  By
switching  on  p53,  therapies  would  selectively  assist  tumor
cells - but not healthy cells - to undergo apoptosis, because
the tumor cells are less responsive to normal environmental
survival signals and are generally exposed to more apoptotic
stress (for example, hypoxia and oncogenic activation). The
importance of establishing the exact p53 status of the tumor
before considering p53-based tumor therapies was empha-
sized several times at the conference, however. For example,
high levels of mutant p53 in cancerous cells could impede the
function of introduced wild-type p53 protein, if the mutant
protein proves able to act in a dominant-negative fashion. 
The plenary talk by Lane focused on how p53 function might
be restored to tumor cells, emphasizing that in many cases
the  p53  gene  is  not  mutated  but  there  is  a  block  in  a
pathway(s) affecting p53. The MDM2 protein featured as a
key target for therapy; in this instance, small peptides that
block the p53-MDM2 interaction or that block MDM2 activ-
ity could serve to activate wild-type p53. Indeed, only the
first  16  amino  acids  of  a  natural  inhibitor  of  MDM2,  the
p14ARF protein,  are  necessary  for  p14ARF to  interact  with
MDM2. In cervical cancer, p53 is targeted for degradation by
the  E3  ligase  activity  of  the  human  papillomavirus  (HPV)
16/18 E6 protein. The drug leptomycin B protects p53 from
degradation by E6 or MDM2, probably by blocking nuclear
export of p53 and, when used in combination with a second
drug, actinomycin D (to inhibit E6 mRNA expression), has
the potential to increase p53 levels further. Although lepto-
mycin B has been found to be toxic in clinical trials, lower
doses  could  still  prove  to  be  effective  in  the  treatment  of
tumors that have wild-type p53, in particular in HPV-associ-
ated cervical cancer, where topical application could be used.
For  treatment  of  tumor  cells  lacking  wild-type  p53,  Lane
proposed  mimicking  the  activity  of  p53  target  genes  (for
example, p21) as a more appropriate approach. 
The p53 protein acts as a transcription factor - but is that all
it does? Karen Vousden (National Cancer Institute, Fredrick,
USA) revealed what she thinks are the capabilities of p53.
Although everyone agrees that p53 can induce the transcrip-
tion of proteins involved in DNA repair (for example, p53R2
and Gadd 45), in cell-cycle arrest (for example, p21CIP and14-3-3)  and  in  apoptosis  (for  example,  PUMA,  Noxa  and
p53AIP1), its apparent ability to induce apoptosis indepen-
dent of transcription was not expected. The evidence for this
independence comes from experiments using a truncation
mutant of p53 (Tr210) that is missing the carboxy-terminal
oligomerization  domain  and  much  of  the  DNA-binding
domain.  Tr210  is  unable  to  induce  the  transcription  of
several  known  p53-inducible  genes  but  can,  nevertheless,
induce apoptosis. Because Tr210 lacks the oligomerization
domain,  it  cannot  be  overcome  by  the  dominant-negative
effect of p53 mutant proteins, that are often highly expressed
in cancer cells, and it is also not targeted for degradation by
either of the E3 ubiquitin ligases, MDM2 or the viral protein
E6. The pro-apoptotic function of Tr210 was mapped to a 37
amino-acid region, raising the possibility of peptide-based
tumor  therapy.  Given  that  many  tumors  have  lost  their
ability to stabilize p53, Vousden has begun screening for spe-
cific  inhibitors  that  would  target  the  E3  ubiquitin-ligase
activity of MDM2 but not that of other E3 ligases. 
As it enhances p53 stability, p14ARF is receiving much atten-
tion.  Intriguingly,  p14ARF is  encoded  by  a  locus  that  also
specifies p16INK4a, a distinct polypeptide that has attracted
equal  attention,  but  this  time  by  virtue  of  its  ability  to
promote  pRb  function.  Whereas  p14ARF acts  by  inhibiting
MDM2-mediated  ubiquitination  and  degradation  of  p53,
p16INK4a inhibits phosphorylation mediated by cyclin-depen-
dent kinase and inactivation of pRb. Gordon Peters (Cancer
Research  UK,  London,  UK)  has  found  that  dermal  fibro-
blasts from certain melanoma-prone individuals have inher-
ited mutations in both alleles of the INK4a/ARF locus that
result  in  loss  of  expression  of  p16INK4a but  no  effect  on
p14ARF function. The cells are insensitive to growth arrest
mediated by the Ras GTPase (a proto-oncogene), and Ras
expression allows cells immortalized by over-expression of
telomerase to form anchorage-independent colonies in soft
agar, although it does not facilitate the growth of these cells
as tumors in nude mice, suggesting that additional genetic
modifications  are  required.  David  Thomas  (University  of
Melbourne, Australia) has found a role for pRb in osteoblast
differentiation and cell-cycle exit that relies on the ability of
pRb  to  interact  with  the  osteoblast  transcription  factor
CBFA1, shedding light on the observation that mutation in
the Rb gene commonly leads to osteosarcoma formation.
Two  melanoma-associated  mutations  of  the  INK4a/ARF
locus, described by Helen Rizos (University of Sydney, Aus-
tralia), specifically affected the sequence of p14ARF but not of
p16INK4a, resulting in cytoplasmic and nucleoplasmic expres-
sion of p14ARF rather than nucleolar expression, and a reduc-
tion in the capacity of p14ARF to activate the p53 pathway.
Searching for proteins that interact with the ARF protein,
Renu Wadhwa (Chugai Research Institute for Medical Sci-
ences, Ibaraki, Japan) has identified a protein, Pex19p, that
interacts with the carboxyl terminus of p19ARF and appears
to  relocate  p19ARF from  the  nucleus  into  the  cytoplasm,
negatively regulating p19ARF function. One caveat, however,
is that Pex19p does not interact with human ARF (p14ARF).
Moshe Oren (The Weizmann Institute, Rehovot, Israel) pre-
sented studies on -catenin, a transcription factor and struc-
tural  component  of  adherens  junctions  that  becomes
activated  in  colorectal  cancer.  He  showed  that  -catenin
induced  the  expression  of  p14ARF (human)  and  p19ARF
(mouse), thereby activating p53, whereas in cells lacking p53
the potential of -catenin as an oncogene was realized.
There has been much hype about the potential use of adeno-
viruses in cancer therapy. One such virus, ONYX-015 is now
in phase III clinical trials for the treatment of head and neck
cancers.  In  a  talk  by  Antony  Braithwaite  (University  of
Otago, Dunedin, New Zealand), however, we were forced to
reconsider  the  usefulness  of  ONYX-015  as  a  cancer  treat-
ment. In theory, ONYX-015, which lacks the E1b55k gene
(the  product  of  which  binds  and  inactivates  p53),  should
only replicate in (and kill) cells that do not have functional
p53 protein (that is, tumor cells). In Braithwaite’s studies,
however, ONYX-015 showed no selectivity for p53-defective
cells,  nor  indeed  for  most  tumor  cells,  and  it  was  in  fact
highly attenuated in its capacity to infect and replicate in any
cell type. 
Genetic susceptibility to cancer
The  RecQ  helicase  family  plays  important  roles  in  DNA
repair. Mutations in genes of this family result in genomic
instability and increased susceptibility to cancer. People with
Bloom’s  syndrome  carry  mutations  in  the  BLM gene,  and
fibroblasts  derived  from  these  individuals  are  resistant  to
p53-mediated apoptosis. Curtis Harris (National Institutes
of Health, Bethesda, USA) showed that, in response to ioniz-
ing radiation, up to 90% of BLM becomes associated with
p53, and that p53 is able to modulate the co-localization of
BLM  with  promyelocytic  leukemia  (PML)  bodies  in  the
nucleus and to disrupt BLM-mediated disruption of Holliday
junctions - the branch point of crossed DNA strands under-
going repair or recombination. The carboxyl terminus of p53
mediates the interaction, and carboxy-terminal peptides of
p53 are able to inhibit both BLM and another RecQ helicase,
WRN, and to induce apoptosis. Phosphorylation of p53 by
protein kinase C prevents the interaction of p53 with BLM
and WRN.
The disease ataxia telangiectasia (A-T) is characterized by
increased  radiation  sensitivity  and  a  predisposition  to
leukemia  and  lymphoma.  A-T  occurs  in  people  lacking
ATM, a protein kinase that is activated by ionizing radiation
and that protects cells from chromosomal damage. Individ-
uals with a single mutant ATM allele are also susceptible to
cancers  (for  example,  breast  cancer).  Martin  Lavin
(Queensland Institute of Medical Research, Brisbane, Aus-
tralia) reported that the most common ATM mutation in
humans is a deletion resulting in the loss of three amino
2 Genome Biology Vol 3 No 6  Verhagen and Lockacids, Ser-Arg-Ile, from the ATM protein. To explore the sig-
nificance of this deletion, a ‘knock-in’ mutation was gener-
ated in the mouse. Animals heterozygous for this mutation
developed tumors, whereas heterozygotes with one normal
ATM allele  and  an  ATM-null  allele  did  not.  This  suggests
that the product of the mutant allele may interfere with the
function  of  the  wild-type  ATM  protein  and,  indeed,  when
introduced  into  cells,  the  mutant  ATM  protein  abolished
radiation-induced  activation  of  the  ATM  kinase,  inhibited
cell survival and increased the occurrence of chromosomal
aberrations. Although the precise mechanism remains to be
elucidated, these studies indicate the potential for mutant
forms of ATM to act in a dominant negative manner in mice
and humans.
Von  Hippel-Lindau  (VHL)  syndrome  is  a  rare  inherited
disease in which individuals with defects in the VHL gene
develop  blood  vessel  tumors  in  the  retina  and  central
nervous system, renal carcinomas and pheochromocytomas
(adrenalmedullary  tumors).  A  major  function  of  the  VHL
gene product, the pVHL protein, is to promote the ubiquitin-
dependent degradation of a hypoxia-inducible transcription
factor, HIF. In VHL syndrome, the absence of pVHL leads to
increased  stability  of  HIF  and  enhanced  expression  of  its
target  genes  -  including  those  for  the  angiogenic  factor,
VEGF (vascular endothelial growth factor). William Kaelin
(Harvard Medical School, Boston, USA) showed that pVHL
and HIF only interact after an intriguing post-translational
modification in which a key proline residue within HIF is
hydroxylated  in  an  iron-  and  oxygen-dependent  manner.
HIF mutants lacking this proline can escape pVHL-depen-
dent degradation and promote tumor formation even in the
presence of pVHL. Thus, pVHL appears to function as an O2
sensor in normal cells; it prevents HIF overexpression and
subsequent downstream events such as angiogenesis.
Cancer models
Our understanding of cancer has greatly benefited from the
generation of mouse models, although they have their limi-
tations. Tyler Jacks (Massachusetts Institute of Technology,
Cambridge, USA) reported on a mouse conditional lung car-
cinoma  model,  in  which  adenoviral  delivery  of  the  Cre
recombinase  enzyme  to  the  lungs  of  genetically  targeted
animals  carrying  loxP insertion  sites  (recognized  by  Cre)
results  in  the  activation  of  an  oncogenic  K-Ras allele.
Tumors develop four weeks after infection with adenoviral
vector, even at the lowest doses of virus tested, and result in
multiple tumors per mouse. Simultaneous K-Ras activation
and expression of a dominant-negative mutant p53 resulted
in metastatic tumors similar to those seen in man. 
The adenoviral Cre-recombinase model has allowed study of
different  stages  of  lung  cancer.  In  addition  to  papillary
adenoma  (positive  using  antibody  to  human  surfactant
protein C) and bronchiolar adenoma (positive using antibody
to  Clara  cell  antigen),  a  third  type  of  tumor,  (positive  for
both these markers) was detected, suggesting either trans-
differentiation  of  tumor  cells  or  expansion  of  a  rare  stem
cell.  Another  focus  of  Jacks’  talk  was  pRb  and  its  role  in
tumorigenesis. Examining Rb+/- mice it was found that 100%
get pituitary tumors and 50% get thyroid tumors but, unlike
humans  of  this  genotype,  none  develops  retinoblastoma.
This highlights a limitation of this mouse model for human
cancer. It is possible that in the mouse model there is func-
tional compensation by pRb family members (for example,
p107 and p130). Indeed, elimination of both pRb and p107
was required for retinoblastoma to develop. Cultures of Rb-/-
mouse embryonic fibroblasts (MEFs) were found to undergo
senescence  in  an  in  vitro growth  assay  whereas  Triple
Knockout  MEFs  (Rb-/-,  p107-/-,  p130-/-)  were  immortal.
Intriguingly, deletion of Rb alone from senescent MEFs by
addition of Cre recombinase to the culture was sufficient to
cause cells to re-enter the cell cycle. This highlights the fact
that loss of pRb during gestation can result in genetic com-
pensation by the organism.
Screening for new tumor suppressors and
oncogenes
Reproducing Bloom’s syndrome in mice by removal of one
copy of the Bloom’s syndrome (BLM) gene provides more
than just a mouse model for a human condition. As Allan
Bradley (The Wellcome Trust Sanger Institute, Hinxton, UK)
reported, it also provides a very powerful tool for screening
for  tumor-suppressor  genes  and  oncogenes.  The  loss  of
heterozygosity  rates  in  Bloom’s  syndrome  mice  is  much
higher  than  in  wild-type  mice,  resulting  in  a  ten-fold
increase in sister-chromatid exchange, an increase in mitotic
recombination  and  an  increased  susceptibility  to  tumors.
Combined  with  arrays  of  bacterial  artificial  chromosomes
(BACs) that allow comparative genome hybridization (CGH),
it is possible to establish where genomic regions are deleted
or amplified in tumors. Another mouse model for screening
involves Cre-loxP-mediated ‘megabase deletion’, to generate
mice with large intra-chromosomal deletions. Although it is
not possible to generate mice with deletions in both copies of
a  given  chromosome  (because  embryonic  lethality  arises
from the loss of too many genes), heterozygous mice can be
examined over time to see if they have increased tumor sus-
ceptibility;  such  an  increase  might  suggest  the  loss  of  a
tumor suppressor in the deleted region that has also sponta-
neously  been  lost  or  mutated  on  the  other  chromosome.
Once again, CGH can be used to establish which genes are
deleted  or  amplified  on  the  originally  intact  chromosome.
These screens are in progress (in Bradley’s group) and have
so far detected known tumor suppressors such as p53 and
adenomatous polyposis coli (APC) genes.
Using a comprehensive set of screening approaches, includ-
ing CGH, cDNA microarray technology and antibody- and
















































































http://genomebiology.com/2002/3/6/reports/4015.3Sloan-Kettering  Cancer  Center,  New  York,  USA)  identified
several  proteins  that  have  altered  expression  in  bladder
cancer.  Of  these,  elevated  cyclin  E  resulting  from  gene
amplification  was  identified  as  a  predictive  marker  for
bladder cancer. Altered expression of moesin, a cell-adhesion
molecule,  and  of  Her-2,  a  member  of  the  epidermal  growth
factor (ErbB/EGF) receptor family of tyrosine kinase signaling
molecules, were also associated with poor prognosis and signif-
icantly reduced survival in transgenic mouse models. 
Signaling pathways
The  notion  that  cell-surface  receptors  for  cytokines  and
growth  factors  can  transmit  both  positive  and  negative
signals to cells via the activation of multiple signal-transduc-
tion pathways has received much attention in recent years.
The importance of this delicate balance between opposing
intracellular  signals  was  highlighted  in  a  talk  by  Matthias
Ernst  (Ludwig  Institute  for  Cancer  Research,  Melbourne,
Australia).  He  has  been  studying  the  gp130  protein,  a
common subunit in several cytokine receptors. Signaling by
gp130 involves the simultaneous activation of the signaling
pathways mediated by the STAT1/3 (signal transducer and
activator  of  transcription)  proteins  and  the  phosphatase
SHP2. ‘Knock-in’ gene targeting was used to generate mice
with mutant gp130 receptors lacking STAT1/3- or SHP2-sig-
naling capabilities. Loss of gp130-mediated STAT signaling
resulted in aberrant repair of mucosal wounds in the gas-
trointestinal  tract,  whereas  loss  of  SHP2  signaling  from
gp130  resulted  in  the  development  of  gastric  adenomas,
raising the possibility that gut homeostasis is tightly regu-
lated by opposing SHP2- and STAT-mediated pathways. Bio-
chemical studies supported this hypothesis. Revealingly, the
gut phenotypes of the different gp130-mutant mice mirrored
those  of  mice  lacking  trefoil  factors  (small  cysteine-rich
secreted  peptides),  TFF1  or  TFF3,  whereas  transfection
experiments  showed  that  the  transcription  of  TFF1 and
TFF3 genes is indeed reciprocally regulated by SHP2- and
STAT-dependent pathways, respectively. 
Immunosurveillance and cancer vaccines
Does immunosurveillance have a role in eliminating tumors?
Initiating the discussion on immunosurveillance was Nobel
laureate Peter Doherty (St Jude Children’s Research Hospi-
tal,  Memphis,  USA).  Although  his  talk  focused  mainly  on
CD8+ T-cell responses to viruses, we were reminded of the
fact  that  CD8+ T-cell-mediated  defense  does  appear  to  be
effective against lymphoma induced by Epstein-Barr virus
(EBV). The development of tetramers (tetrameric complexes
of the major histocompatibility complex, MHC, plus peptide)
has  greatly  facilitated  the  detection  of  antigen-specific
T cells.  They  will  allow  the  question  of  tumor-specific
immunosurveillance to be more carefully addressed because
the tetramer interacts only with the T-cell-antigen receptors
that are specific for the tetramer (that is, specific for that
MHC-plus-peptide complex).
Examining  further  the  role  of  tumor  immunosurveillance,
Mark Smyth (Peter MacCallum Cancer Institute, Melbourne,
Australia) has been investigating spontaneous tumor devel-
opment in aging mice that carry null mutations in a range of
genes involved in normal immune-system function. He has
found that mice lacking perforin, a key effector molecule in
cytotoxic killing by CD8+ cells, and also lacking interferon 
(IFN are  more  susceptible  to  late-onset  adenocarcinoma
than  are  wild-type  mice,  supporting  a  role  for  tumor
immunosurveillance in epithelial tissues. 
Spontaneous regression of melanomas has been frequently
observed and shown to be associated with T-cell infiltrates.
On the basis of this observation, Jonathon Cebon (Ludwig
Institute,  Melbourne,  Australia)  and  colleagues  have  been
trying to develop vaccines including a peptide/peptides in
order to generate a T-cell response against melanoma-spe-
cific  antigens.  The  vaccine  has  been  combined  with  Flt-3
ligand  in  an  attempt  to  enhance  antigen  presentation  by
dendritic  cells.  So  far,  the  frequency  of  antigen-specific
T cells,  determined  using  tetramers  after  three  rounds  of
immunization, has been very low (less than 1%), while virus-
specific T cells have been shown to represent up to 18% of
the blood CD8+ T-cell population in response to EBV. 
Failed  attempts  to  immunize  against  tumor  antigens  are
thought to result from either a lack of antigen-specific T-cell
precursors or ineffective activation and expansion of these
cells when challenged with tumor antigen. An approach to
overcome  this,  described  by  Michael  Kershaw  (National
Institutes  of  Health,  Bethesda,  USA)  involved  the  use  of
dual-specificity  T  cells.  The  endogenous  T-cell  receptor
within these cells is specific for allo-antigen, traditionally a
very powerful immunogen, whereas specificity for the tumor
is conferred by an introduced chimeric receptor comprising
the  extracellular  single-chain  form  of  anti-folate-binding
protein (an antigen associated with ovarian cancer) linked to
the intracellular domain of FcR the gamma signaling chain
of the Fc receptor complex). Although no expansion of the
dual-specificity T cells was observed when they were trans-
ferred alone into mice bearing tumors, when combined with
allogeneic stimulation the cells not only expanded but also
resulted in an inhibition of tumor growth. The response was
much greater when allogeneic immunization was adminis-
tered subcutaneously rather than intravenously. 
Other markers of cancer
The nine-member Pax family of proteins comprises transcrip-
tion factors that are normally expressed only during develop-
ment but are often over-expressed in cancer. Michael Eccles
(University  of  Otago,  Dunedin,  New  Zealand)  presented
4 Genome Biology Vol 3 No 6  Verhagen and Lockevidence  that  expression  of  one  of  these  proteins,  Pax2,
confers resistance to apoptotic stimuli. 
In discussing other markers of cancer, Jane Visvader (The
Walter and Eliza Hall Institute of Medical Research, Mel-
bourne,  Australia)  argued  for  a  possible  link  between
LMO4, a member of the nuclear LIM-only group of tran-
scriptional  regulators  containing  two  tandem  LIM  zinc-
binding  domains,  and  breast  tumorigenesis.  LMO4  is
normally  expressed  developmentally  in  the  mammary
gland and was found to be overexpressed in about 50% of
primary human breast cancers. In addition, overexpressing
LMO4  in  mouse  mammary-epithelial  cells  was  shown  to
inhibit their differentiation. Searching for a mechanism for
LMO4  function,  Visvader  and  colleagues  identified  both
the  cofactor  carboxy-terminal  binding  protein  (CtBP,  a
protein targeted by adenoviral E1A) and tumor suppressor
protein BRCA1 as binding partners for LMO4 and demon-
strated repression by LMO4 of BRCA1-mediated transacti-
vation in mammalian cells. 
Loss of heterozygosity of the long arm of chromosome 16 is
common in breast tumorigenesis. Narrowing the region to
16q24.3, David Callen and colleagues (Bionomics Ltd, Aus-
tralia) have found a gene, MTG16, the expression of which is
absent from approximately 50% of breast cancers. Re-intro-
duction of MTG16 into different breast-cancer-derived cell
lines dramatically reduced their proliferative capacity, sug-
gesting that this protein may be a novel tumor suppressor.
Karen Boucaut (Queensland Institute of Medical Research,
Brisbane,  Australia)  presented  evidence  that  testisin,  a
serine proteinase, is a candidate tumor suppressor. Testisin
is  normally  expressed  in  pre-meiotic  spermatocytes  but  is
not expressed in testicular tumors that are thought to arise
from germ cells. The absence of testisin expression from the
tumors was shown to correlate with extensive methylation of
a CpG island (a 200 bp region of high GC content) within the
5-untranslated  region.  Furthermore,  re-introduction  of  a
membrane-bound form of testisin into the tumor cell line
Tera-2 resulted in the formation of smaller tumors in the
testes of inoculated immunodeficient SCID mice compared
to control-transfected cells. 
Metalloproteinases as therapeutic targets
Metalloproteinases  are  a  large  family  of  proteins  that
mediate degradation of the extracellular matrix. These pro-
teins have been implicated in tumor metastasis and, for this
reason, are thought to be good targets for therapeutic inter-
vention.  Using  xenograft  models  in  nude  mice,  Mark
Waltham (St Vincent’s Institute, Melbourne, Australia) has
tested the effectiveness of prinomastat, a potent inhibitor of
select  metalloproteinases,  for  treatment  against  breast
cancer  and  breast-to-bone  metastasis.  A  reduction  in
primary tumor growth and bone metastasis in response to
the  drug  was  observed,  resulting  in  significantly  reduced
osteolytic bone damage, although metastasis to soft tissue
was unaffected. As reported by Lynn Matrisian (Vanderbilt
University, Nashville, USA), however, the results of clinical
trials of a panel of different metalloproteinase inhibitors for
the treatment of a variety of cancers have been generally dis-
appointing. Several factors could have contributed to this,
including  the  finding  that  in  one  trial  a  drug  was  used
although the target metalloproteinase was absent from the
tumor, and in another trial a reduction in tumor mass was
used as a criterion for effectiveness despite the fact that met-
alloproteinase  inhibitors  are  cytostatic  (preventing  cell
growth) rather than cytotoxic (damaging to cells). Metallo-
proteinase inhibitors were not without benefit, however, and
in  one  trial  improved  the  outcome  of  patients  who  had
received  prior  chemotherapy.  The  need  to  treat  patients
earlier and to refine the treatments for the specific tumors
being targeted was highlighted. 
As  we  try  to  unravel  the  mysteries  of  tumorigenesis,  it  is
becoming increasingly clear that for every type of cancer -
and there are many - deregulation and/or mutation of a spe-
cific  subset  of  genes  is  likely  to  be  involved.  The  affected
genes  may  include  oncogenes  that  become  activated  or
amplified  leading  to  enhanced  cell  growth,  or  tumor  sup-
pressors that are lost and fail to oppose it. For every tumor
we  need  to  know  the  precise  molecular  basis  of  disease:
which genes have been mutated or silenced, and what pro-
teins  are  over-represented  or  absent?  The  importance  of
‘knowing  your  tumor’  so  that  individually  tailored  tumor
therapy can be put into place was an emerging theme at the
Lorne Cancer Conference and one that seems likely to have
an impact in the clinic in the not too distant future. 
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